JLB & Associates’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10M | Sell |
209,088
-419
| -0.2% | -$18K | 1.34% | 27 |
|
|
2026
Q1 | $7.7M | Sell |
209,507
-1,815
| -0.9% | -$86K | 1.11% | 35 |
|
|
2025
Q4 | $10.8M | Sell |
211,322
-8,302
| -4% | -$425K | 1.45% | 27 |
|
|
2025
Q3 | $12.2M | Buy |
219,624
+1,426
| +0.7% | +$83.5K | 1.6% | 25 |
|
|
2025
Q2 | $15.1M | Sell |
218,198
-1,041
| -0.5% | -$70.8K | 2.1% | 19 |
|
|
2025
Q1 | $15.2M | Buy |
219,239
+4,874
| +2% | +$403K | 2.12% | 20 |
|
|
2024
Q4 | $18.4M | Buy |
214,365
+1,216
| +0.6% | +$131K | 2.5% | 17 |
|
|
2024
Q3 | $25.4M | Sell |
213,149
-7,334
| -3% | -$978K | 3.27% | 6 |
|
|
2024
Q2 | $31.5M | Sell |
220,483
-8,677
| -4% | -$1.15M | 4.25% | 2 |
|
|
2024
Q1 | $29.4M | Sell |
229,160
-22,079
| -9% | -$2.63M | 3.91% | 4 |
|
|
2023
Q4 | $26M | Sell |
251,239
-18,791
| -7% | -$1.86M | 3.74% | 4 |
|
|
2023
Q3 | $24.6M | Sell |
270,030
-12,198
| -4% | -$1.07M | 3.85% | 3 |
|
|
2023
Q2 | $22.8M | Sell |
282,228
-12,070
| -4% | -$986K | 3.25% | 8 |
|
|
2023
Q1 | $23.4M | Sell |
294,298
-4,572
| -2% | -$324K | 3.52% | 4 |
|
|
2022
Q4 | $20.2M | Sell |
298,870
-8,798
| -3% | -$516K | 3.22% | 7 |
|
|
2022
Q3 | $15.3M | Sell |
307,668
-2,312
| -0.7% | -$124K | 2.72% | 14 |
|
|
2022
Q2 | $17.3M | Sell |
309,980
-5,040
| -2% | -$280K | 2.94% | 9 |
|
|
2022
Q1 | $17.5M | Buy |
315,020
+38
| +0% | +$1.95K | 2.62% | 14 |
|
|
2021
Q4 | $17.6M | Sell |
314,982
-1,584
| -0.5% | -$85.8K | 2.5% | 15 |
|
|
2021
Q3 | $15.2M | Sell |
316,566
-10,522
| -3% | -$509K | 2.41% | 16 |
|
|
2021
Q2 | $13.7M | Buy |
327,088
+13,158
| +4% | +$510K | 2.13% | 21 |
|
|
2021
Q1 | $10.6M | Buy |
313,930
+2,710
| +0.9% | +$96.5K | 1.74% | 27 |
|
|
2020
Q4 | $10.9M | Buy |
311,220
+2,576
| +0.8% | +$89K | 1.8% | 23 |
|
|
2020
Q3 | $10.7M | Buy |
308,644
+3,156
| +1% | +$105K | 1.97% | 20 |
|
|
2020
Q2 | $10M | Sell |
305,488
-3,660
| -1% | -$117K | 2% | 19 |
|
|
2020
Q1 | $9.3M | Sell |
309,148
-12,888
| -4% | -$384K | 2.21% | 21 |
|
|
2019
Q4 | $9.32M | Sell |
322,036
-4,280
| -1% | -$119K | 1.71% | 27 |
|
|
2019
Q3 | $8.44M | Buy |
326,316
+8,976
| +3% | +$227K | 1.67% | 30 |
|
|
2019
Q2 | $8.1M | Buy |
317,340
+2,720
| +0.9% | +$67.2K | 1.64% | 30 |
|
|
2019
Q1 | $8.23M | Buy |
314,620
+442
| +0.1% | +$10.9K | 1.74% | 28 |
|
|
2018
Q4 | $7.24M | Sell |
314,178
-14,816
| -5% | -$329K | 1.76% | 27 |
|
|
2018
Q3 | $7.75M | Buy |
328,994
+2,944
| +0.9% | +$71.8K | 1.66% | 27 |
|
|
2018
Q2 | $7.52M | Buy |
326,050
+35,610
| +12% | +$846K | 1.6% | 29 |
|
|
2018
Q1 | $7.15M | Buy |
290,440
+30,096
| +12% | +$790K | 1.54% | 31 |
|
|
2017
Q4 | $6.99M | Buy |
260,344
+34,172
| +15% | +$869K | 1.52% | 33 |
|
|
2017
Q3 | $5.45M | Buy |
226,172
+1,890
| +0.8% | +$42.7K | 1.33% | 36 |
|
|
2017
Q2 | $4.81M | Buy |
+224,282
| New | +$4.53M | 1.22% | 37 |
|
|
2016
Q4 | $4.33M | Buy |
241,350
+4,648
| +2% | +$84.3K | 1.17% | 37 |
|
|
2016
Q3 | $4.92M | Buy |
236,702
+17,542
| +8% | +$435K | 1.36% | 35 |
|
|
2016
Q2 | $5.89M | Sell |
219,160
-18,906
| -8% | -$518K | 1.67% | 29 |
|
|
2016
Q1 | $4.21M | Buy |
238,066
+44,946
| +23% | +$1.2M | 1.08% | 38 |
|
|
2015
Q4 | $5.61M | Buy |
193,120
+5,590
| +3% | +$155K | 1.73% | 27 |
|
|
2015
Q3 | $5.08M | Buy |
187,530
+2,408
| +1% | +$68.2K | 1.64% | 28 |
|
|
2015
Q2 | $5.07M | Sell |
185,122
-254
| -0.1% | -$7.14K | 1.57% | 31 |
|
|
2015
Q1 | $4.95M | Buy |
185,376
+5,826
| +3% | +$134K | 1.55% | 31 |
|
|
2014
Q4 | $3.8M | Buy |
179,550
+500
| +0.3% | +$11.2K | 1.26% | 35 |
|
|
2014
Q3 | $4.26M | Sell |
179,050
-1,244
| -0.7% | -$28.6K | 1.53% | 29 |
|
|
2014
Q2 | $4.16M | Buy |
180,294
+7,582
| +4% | +$167K | 1.51% | 30 |
|
|
2014
Q1 | $3.94M | Buy |
172,712
+4,962
| +3% | +$106K | 1.47% | 32 |
|
|
2013
Q4 | $3.1M | Buy |
167,750
+9,010
| +6% | +$157K | 1.18% | 37 |
|
|
2013
Q3 | $2.69M | Buy |
158,740
+6,320
| +4% | +$106K | 1.13% | 39 |
|
|
2013
Q2 | $2.36M | Buy |
+152,420
| New | +$2.54M | 1.08% | 44 |
|
Other funds holding NVO
F
JLB & Associates's NVO Position: Q2 2026 in Review
JLB & Associates reduced its Novo Nordisk (NVO) stake by 0.2% in Q2 2026, selling an estimated $18K and leaving 209,088 shares worth $10M. The position accounts for 1.34% of the portfolio, ranked #27.
JLB & Associates first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $31.5M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- JLB & Associates held 209,088 shares of Novo Nordisk worth $10M as of Q2 2026.
- JLB & Associates sold 419 Novo Nordisk shares in Q2 2026, an estimated $18K.
- Novo Nordisk made up 1.34% of JLB & Associates's portfolio in Q2 2026, its #27 holding.
- JLB & Associates first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
- JLB & Associates's Novo Nordisk position peaked at $31.5M in Q2 2024.
- 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on JLB & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.